Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 257 Carcinoma, Intraductal, Noninfiltrating 24 Breast Carcinoma In Situ 21 Neoplasms 12 Neoplasm Metastasis 12 Breast Neoplasms, Male 12 Ovarian Neoplasms 10 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Prostatic Neoplasms 5 Endometrial Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Astrocytoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Medulloblastoma 2 Liver Neoplasms 2 Infertility 2

Interventions

lutetium Lu 177 dotatate 34 Everolimus 33 lanreotide 13 gallium Ga 68 dotatate 13 Temozolomide 13 Magnetic Resonance Spectroscopy 13 Nivolumab 12 pembrolizumab 11 Octreotide 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 surufatinib 8 Sunitinib 8 Specimen Handling 7 Carboplatin 7 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Lutetium-177 5 Ipilimumab 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5 Bevacizumab 5 telotristat ethyl 4 olaparib 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × Tamoxifen × Clear all

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡